FDA Rounds Up Biliary Stent Makers On Off-label Promotion
This article was originally published in The Gray Sheet
Executive Summary
FDA gathered biliary stent manufacturers to discuss how to prevent off-label marketing for peripheral vascular disease while it clarifies the regulatory pathway for vascular stents
You may also be interested in...
Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts
Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.
Abbott Settlement With DOJ Highlights Feds’ Anti-Fraud Efforts
Abbott will pay $5.47 million to resolve allegations that it paid physicians for teaching assignments, speaking engagements and conferences with the expectation that they would in return facilitate product purchases at their hospitals.
FDA Project Focuses On Imaging To Improve Stent Design
Research supported by FDA's "critical path" initiative suggests that computed tomography is a useful tool for studying the mechanical dynamics of stents placed in leg arteries, among the more challenging parts of the body for device use